MATERNITY

NURSING EFFECTIVENESS AND SAFETY OF HUMAN PAPILLOMAVIRUS VACCINATION

IN HIV-INFECTED PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS

GROUP II (TWO) dr. SOETARTO DKT YOGYAKARTA

ARRANGED BY :

1. Guntur Setyowicaksono (142022030337)

2. Sunarto (142022030382 )
3. Daryono (142022030345)
4. Marriana Dwi Lestari (142022030336)
5. Rohmatin (142022030339)
6. Ely Sulisiyah (142022030338)

GRADUATE NURSING PROGRAM

FACULTY OF HEALTH SCIENCES
MUHAMMADIYAH KUDUS UNIVERSITY
IN 2022
 BACKGROUND
● Vaccine available prophylaxis _ for protect from infection by HPV can tolerated with good and
very immunogenic .
● People with HIV have risk more tall caught HPV infection and cancer related
HPV because response more immunity _ low , and because interaction virus.
● we did review systematic RCTs for evaluate efficacy and security HPV vaccine in infected people HIV compared with
placebo or without intervention in Thing seroconversion , infection , neoplasm , effect
aside , amount CD4 + T cells and HIV viral load.
● Group vaccine show level seroconversion approach 100% for every vaccine and level distant antibodies _ more tall to type
vaccine HPV, compared with group placebo (MD= 4333.3, 95% CI 2701.4; 5965.1 GMT EL.U./ml for HPV type 16 and MD=
1408.8, 95% CI 414.8; 2394.7 GMT EL.U./ml for HPV type 18). Also no there is difference in terms of effect severe side
effects ( RR = 0.6, 95% CI 0.2; 1.6) and no there is effect severe side effects ( RR= 0.6 , 95% CI 0.9; 1.2) between group
vaccine and placebo . Results secondary , like amount CD4 + T cells and HIV viral load
, no different between group (MD= 14.8, 95% CI ÿ 35.1; 64.6 cells / μ l and MD= 0.0, 95% CI ÿ 0.3; 0.3 log10
RNA copies /ml, respectively )

2
 POPULATION
 Studies including people with HIV: women aged 18-25 years with group mean age
vaccine 21.6 ± 2.21 years and group placebo 22.7 ± 1.725; MSMÿ18 years with
average age group vaccine 37.3 ± 10.6 years and group control 40.5±10.0227;
child 7-12 years old with group mean age 10 year vaccine (95% CI 9.7-10.3) and
placebo 9.9 years (95% CI 9.4-10.4)26; MSM and female ÿ27 years with group
mean age vaccine 47 (IQR 40–52) and placebo 48 (IQR 42–53)28.

 RCTs were performed Among in 2008 and 2014 in South Africa, Spain , the US,
and Brazil . For one study date beginning and end not reported 26. Four studies
randomized a total of 950 participants . kindly whole , group vaccine consists of
511 HIV+ patients , ranging from between 61 and 288 participants per study .
Group placebo consists of 439 HIV+ patients , ranging from between 59 and 287
per study .

3
RESEARCH METHODOLOGY
 Discussion

 Completeness whole and application proof

 Certainty Proof

 Review

 Deal and disagreement with review systematic other

 Implications for practice

 Implications for study


RESEARCH INTERVENTION “
tree study evaluate immunogenicity and security 4vHPV26–28 and
one evaluate reactogenicity and security 2vHPV25.

 In one experiment , participants has accept vaccine HPV 16/18

AS04 adjuvant or placebo at 0, 1, and 6 months 25.

 In three test others , vaccines quadrival and placebo given at 0, 8,

24 weeks . Not none of _ included research _ report use of 9vHPV.

5
 RESEARCH RESULT

● Results in primary study reported on point different time _ as reported _ in Table Supplement S3. Only point time
up to 12 months after commencement Suite vaccinations considered . _
● Based on data availability , we decided for evaluate results on point time following :
a. Results seroconversion rated after end series vaccination ( months 725,26 and week 2827). •
b. Infection anal and oral assessed as infection persistent During period research , incl
infection single detection on last visit28 .
c. AIN was assessed as High Level AIN on results anal biopsy during period studies
( “ full ITT approach ” as stated by author ) 28 . •
d. Abnormal Anal Cytology assessed after end series vaccination ( week 52)28.
e. AE results were assessed after end series vaccination ( 725 months, 626 months , 2827 weeks and
week 4828).

6
ADVANCED
f. Results Dead all reason rated after end series vaccination
( month 1225 , month 626 and week 4828).
g. Results amount CD4 + T cells were assessed after 2nd vaccination ( month

225,26 , and week 827) and after end series vaccination ( month
625,26, and week 2827).
h. HIV VL results were assessed after 2nd vaccination ( 225 months and week
827) and after end Suite vaccination ( month 625 and
week 2827).

7
Thanks!